8-K: Alaunos Therapeutics Secures $850,000 Through Private Preferred Stock Offering

Alaunos Therapeutics, Inc. has completed a private offering of Series A-2 Convertible Preferred Stock, raising $850,000 to bolster its financial position.

Summary

• Alaunos Therapeutics, Inc. (TCRT) entered into a Subscription Agreement on June 24, 2025, to issue and sell Series A-2 Convertible Preferred Stock in a private offering.
• The company raised an aggregate purchase price of $850,000 by selling shares of Series A-2 Preferred Stock at $1,000 per share.
• The Series A-2 Preferred Stock carries a cumulative dividend rate of 10% per annum, payable in additional shares of Series A-2 Preferred Stock, accruing daily and compounding quarterly.
• Holders of Series A-2 Preferred Stock are entitled to vote alongside common stockholders on an as-converted basis, with each preferred share having votes equal to the number of common shares it can convert into.
• The preferred stock has an initial fixed conversion price of $4.49 per share into common stock, subject to proportional adjustments.
• In the event of liquidation, dissolution, or winding up, Series A-2 Preferred Stock holders are entitled to receive their $1,000 stated value per share plus all unpaid accrued dividends, ranking senior to common stock.
• The securities were offered and sold in a private placement under Section 4(a)(2) and/or Rule 506(b) of Regulation D and have not been registered under the Securities Act.
• The company is obligated to maintain a sufficient number of authorized but unissued common shares to cover potential conversions and unpaid dividends, and will take corporate action, including seeking stockholder approval, if necessary.
• Purchasers in the offering include Water Mill Asset Management Co. ($600,000 for 600 shares) and Jaime Vieser ($250,000 for 250 shares).

Sentiment

Score: 3

Explanation: While the capital raise provides immediate liquidity, the small amount and the high cost of capital (10% cumulative dividend, senior preference) suggest potential financial challenges and unfavorable terms for existing common shareholders, indicating a negative outlook.

Positives

• The company successfully secured $850,000 in capital, providing immediate funding for its operations.
• The Series A-2 Preferred Stock offers a senior liquidation preference and cumulative dividends, which are attractive terms for investors, facilitating the capital raise.
• The company has committed to filing a shelf registration statement within 90 calendar days to allow for the resale of the underlying common shares, providing a potential liquidity path for investors.

Negatives

• The 10% annual dividend rate on the Series A-2 Preferred Stock, payable in kind, represents a significant ongoing cost and potential for future dilution for existing common shareholders.
• The preferred stock's senior ranking in liquidation and dividends places common stockholders in a subordinate position.
• The capital raise amount of $850,000 is relatively small for a publicly traded company, which might suggest challenges in securing larger financing or on more favorable terms.

Risks

• The securities offered have not been registered under the Securities Act or applicable state securities laws, meaning they are restricted and subject to limitations on transferability.
• Investment in these securities involves a high degree of risk, and purchasers could lose their entire investment.
• The company has no obligation or intention to register the securities or underlying shares, or to take action to permit sales under Rule 144, except for the specific shelf registration commitment within 90 days, meaning investors may bear economic risks for an indefinite period.
• Future conversion of the Series A-2 Preferred Stock into common stock will result in dilution for existing common shareholders.
• If the number of authorized common shares is insufficient for conversion, the company will limit conversions proportionally until corporate action (potentially requiring stockholder approval) is taken to increase authorized shares.

Future Outlook

The document indicates the company's commitment to file a shelf registration statement within 90 calendar days following the closing of the offering to facilitate the resale of the underlying common shares by the purchasers. This suggests a future action aimed at providing liquidity for the new investors.

Industry Context

NA

Corporate Governance

Stakeholder Impact

• Shareholders (Common Stock): Face potential dilution from the conversion of preferred stock and are subordinated to preferred shareholders in terms of dividends and liquidation preference. The 10% dividend rate represents a cost to the company that could impact common shareholder returns.
• Investors (Series A-2 Preferred Stock): Benefit from a high 10% cumulative dividend, senior liquidation preference, and the right to convert into common stock, with a commitment from the company to facilitate resale through a shelf registration.

Next Steps

• The company will submit or file a shelf registration statement on Form S-3 (or Form S-1 if not available) with the SEC within 90 calendar days following the closing of the offering.
• The company will use commercially reasonable efforts to have the registration statement declared effective as soon as practicable after filing.

Key Dates

Recommendation

Keywords

Alaunos Therapeutics, TCRT, Series A-2 Convertible Preferred Stock, Private Placement, Capital Raise, SEC Filing, 8-K, Preferred Stock, Convertible Securities, Equity Financing, Biotechnology, Investment, Dilution, Dividends, Liquidation Preference